Evidence map›Paper›PMID 35411434›Full record

ReviewCellular and molecular neurobiology2023

Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment.

Ali Karimi Sisakht, Mohammad Malekan, Farbod Ghobadinezhad, Seyedeh Negar Mousavi Firouzabadi, Ameneh Jafari, Seyed Mohammad Ali Mirazimi, Banafshe Abadi, Rana Shafabakhsh, Hamed Mirzaei

Open access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Drosophila melanogaster as a Model System for Human Glioblastoma.Advances in experimental medicine and biology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. MicroRNA-383: A tumor suppressor miRNA in human cancer.Frontiers in cell and developmental biology · 2022
    Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Ali Karimi SisakhtBrain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Mohammad MalekanBrain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Farbod GhobadinezhadBrain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Seyedeh Negar Mousavi FirouzabadiBrain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Ameneh JafariAdvanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Seyed Mohammad Ali MirazimiSchool of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Banafshe AbadiBrain Cancer Research Core (BCRC), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Rana ShafabakhshResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran.
Hamed MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran. mirzaei-h@kaums.ac.ir.ORCID http://orcid.org/0000-0002-9399-8281
Kashan University of Medical Sciences · IRKerman University of Medical Sciences · IRAcademic Center for Education, Culture and Research · IRKermanshah University of Medical Sciences · IRUniversal Scientific Education and Research Network · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most frequent malignancy among primary brain tumors in adults and one of the worst 5-year survival rates (< 7%) among all human cancers. Till now, treatments that target particular cell or intracellular metabolism have not improved patients' survival. GBM recruits healthy brain cells and subverts their processes to create a microenvironment that contributes to supporting tumor progression. This microenvironment encompasses a complex network in which malignant cells interact with each other and with normal and immune cells to promote tumor proliferation, angiogenesis, metastasis, immune suppression, and treatment resistance. Communication can be direct via cell-to-cell contact, mainly through adhesion molecules, tunneling nanotubes, gap junctions, or indirect by conventional paracrine signaling by cytokine, neurotransmitter, and extracellular vesicles. Understanding these communication routes could open up new avenues for the treatment of this lethal tumor. Hence, therapeutic approaches based on glioma cells` communication have recently drawn attention. This review summarizes recent findings on the crosstalk between glioblastoma cells and their tumor microenvironment, and the impact of this conversation on glioblastoma progression. We also discuss the mechanism of communication of glioma cells and their importance as therapeutic targets and diagnostic and prognostic biomarkers. Overall, understanding the biological mechanism of specific interactions in the tumor microenvironment may help in predicting patient prognosis and developing novel therapeutic strategies to target GBM.

Indexed as

Brain NeoplasmsGlioblastomaGliomaAdultCell Membrane StructuresCytokinesHumansNanotubesTumor MicroenvironmentCytokinesTunneling NanotubesCellular mechanismGlioblastomaTherapy

Identifiers

PMID35411434
PMCPMC11415179
OpenAlexW4223415056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.